睿知中国医院研究地图
候选清单

即将招募多发性骨髓瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06895512,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patient must have an ECOG performance status score of 0.

    入选标准第 5 条

  3. Patient has a history of malignancy (other than MM) within 3 years before randomization .

    排除标准第 5 条

    Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).

    排除标准第 8 条

  4. A WOCBP must have a negative serum pregnancy test at screening within 72 hours prior to randomization.

    入选标准第 8 条

    Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes).

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06895512,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Capable to understand and sign the ICF.
  2. Patients aged ≥ 18 years .
  3. Patient must have documented multiple myeloma (MM) satisfying the International Myeloma Working Group (IMWG) diagnostic criteria for MM.
  4. Newly diagnosed, untreated and not considered candidate for autologous stem cell transplantation (ASCT).
  5. Patient must have an ECOG performance status score of 0.
  6. Patient must have pretreatment clinical laboratory values.
  7. Contraceptive use by men or women should be consistent with local regulations.
  8. A WOCBP must have a negative serum pregnancy test at screening within 72 hours prior to randomization.

排除标准:Exclusion Criteria:

  1. Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  2. Patient has plasma cell leukemia or POEMS syndrome .
  3. Patient has prior or current systemic therapy or ASCT for MM before randomization.
  4. Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher.
  5. Patient has a history of malignancy (other than MM) within 3 years before randomization .
  6. Patient has clinical signs of meningeal involvement of MM.
  7. Patient has known COPD, persistent asthma, or a history of asthma within the last 2 years.
  8. Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).
  9. Patient is known to have active hepatitis B or C.
  10. Patient has any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results.
  11. Patient has clinically significant cardiac disease.
  12. Patient has known allergies, hypersensitivity, or intolerance to treatment drugs.
  13. Patient has history of drug abuse or substance abuse.
  14. Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes).
  15. Patient had radiation therapy within 14 days of randomization.
  16. Patient had plasmapheresis within 28 days of randomization.
  17. Patient had major surgery within 28 days before randomization.
  18. Patient in clinical trials of any other drug or device within 3 months before randomization.
  19. Patient has any condition could prevent, limit, or confound the protocol-specified assessments.

引自 ClinicalTrials.gov, NCT06895512, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06895512,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06895512